glens0
5月前
INBS News,
Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Thanet Earth, the UK’s largest greenhouse complex, has adopted its Intelligent Fingerprinting Drug Screening System for in-house drug testing.
“We are thrilled to partner with Intelligent Fingerprinting to enhance our approach to workplace safety,” said Emma Bullock, Head of People at Thanet Earth. “Fingerprint drug testing allows us to ensure that our team is operating in a safe and efficient manner without interrupting our daily operations.”
Thanet Earth is a leader in the UK’s horticultural sector, producing millions of tomatoes, cucumbers, and peppers annually for major retailers nationwide. The company is renowned for its state-of-the-art approach to sustainable farming, integrating cutting-edge technology to optimize yield and environmental impact.
With the implementation of the Intelligent Fingerprinting Drug Screening System, Thanet Earth will be able to conduct workplace drug testing quickly, discreetly, and effectively. This capability is crucial in maintaining safety within the high-paced food production environment, where even minor disruptions can have significant downstream effects.
Helter Skelter
6月前
As of May 6, 2024, there were 3,117,049 shares of the registrant’s Common Stock issued and outstanding.
Cash & Equivs $9.4M with a quarterly Burn Rate (loss) of approx $2.5M per Q. They may have to have another offering before they receive, hopefully soon, FDA Clearance to market & sell...looks like a pretty safe long (in & out as it goes) play, very interesting product JMO 😺
$INBS FINS as of March 31, 2024:
Helter Skelter
6月前
Thought their FINS were released today but apparently not. Started DDing this puppy and their product looks quite interesting... Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. Additionally, the Company’s biosensor platform has the potential to test for various indications, ranging from immunological conditions to communicable diseases. The Company’s current customer segments include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.?
For more information, visit:?http://www.ibs.inc/$INBS
Invest, barefoot, crossing the rubicon, lol...
Invest-in-America
6月前
Hey, on that note, I remember when iHub's "MONSTA-GAINS" & "CHIVITO" --- remember those fellows(??) --- made your identical observations YEARS ago now, after the SEC cleaned-up the OTC, & thereby left no alternative except for the NASDAQ itself to become increasingly CORRUPT!! (Funny stuff, except when one gets SUCKERED by these daily GAP-&-DROPPERS!!)
Helter Skelter
6月前
Lol, sorry, not a tool, just going from aft and premarkert into the regular market, the Rubicon, point of no return...a lot of these p&d pOps like to do it in the dead of night under cover of dark...these ihub charts (classic) illuminate the activity...but ya gotta screen capture the activity...
$INBS
reena969
6月前
Helter Skelter, I'm not familiar with your Rubicon indicator, but it definitely caught my attention. I'm always open to exploring new tools to add to my trading arsenal. However, my A.I seems a bit uncertain about it...... She's called " Bestie"
"The Rubicon Trading Indicator doesn't seem to be a well-known, widely referenced tool in mainstream technical analysis literature or trading platforms. It could refer to a proprietary or custom indicator used by specific traders or groups, or it might be a lesser-known tool in a particular trading community."
Invest-in-America
6月前
INBS, Intelligent Bio Systems (3-Mil. Flt.): $1.58, 21%; (post-M) 30%; recent news seeks FDA o.k. for initial study fast finger-print-sweat Opiod tests, etc.; all things fast med. testing patients, suspects, diseases, drunk, etc.; New York.
AveragePenny
7月前
Intelligent Bio Solutions Inc. (Nasdaq: $INBS ) Announces Major Steps Towards FDA Clearance and U.S. Launch.
https://thestreetreports.com/intelligent-bio-solutions-inc-nasdaq-inbs-announces-major-steps-towards-fda-clearance-and-u-s-launch/
In July 2024, Intelligent Bio Solutions Inc. (Nasdaq: INBS) revealed that three UK-based manufacturers adopted its Fingerprint Drug Screening System, renowned for its fast, intelligent, and non-invasive drug detection through fingertip sweat. This innovation’s biocompatibility has propelled it towards FDA clearance, with plans for a U.S. launch in 2025.
On August 1, Intelligent Bio Solutions entered a strategic partnership with CenExel, a nationwide clinical research site network operator. This collaboration is part of an FDA clinical study plan, involving a method comparison clinical study.
Under the study, 135 healthy adult subjects across three sites will participate in tests comparing the fingerprint sweat opiate screening results with those from the traceable LC-MS/MS method, the current gold standard.
This partnership and study are the final stages of Intelligent Bio Solutions’ clinical study plan. Over the past two months, the company has made significant progress and is on track to submit its 510(k) application to the FDA in Q4 2024. The company praised the efforts of its clinical study partners and team for their role in the smooth progression of this process.
Intelligent Bio Solutions Inc. is moving closer to revolutionizing drug screening with its innovative, non-invasive solutions.
Here are four healthcare companies under $10 demonstrating robust market trends, volume, and awareness:
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) – Focuses on therapies for central nervous system disorders.
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) – Specializes in cancer immunotherapy products.
Savara Inc. (NASDAQ: SVRA) – Develops therapies for rare respiratory diseases.
Eyenovia, Inc. (NASDAQ: EYEN) – Innovates in ophthalmic treatments.
These companies are actively involved in the healthcare sector, showcasing market strength through their innovative products and services.
AveragePenny
8月前
$INBS Intelligent Bio begins dosing for non-invasive drug screening technology
https://finance.yahoo.com/news/intelligent-bio-begins-dosing-non-103309318.html
US-based company Intelligent Bio Solutions has completed patient screening and will start dosing and sampling in the pharmacokinetic (PK) study for its fingerprint drug screening technology.
The study is expected to support the planned 510(k) submission to the US FDA, intended for Q4 of this year. Intelligent Bio expects the study to complete recruitment by the end of June, with a review of the PK study results expected to be finalised by the end of next month.
The news comes on the heels of last week’s announcement of the company’s decision to shift its “operating structure from a UK-based model to a global framework”. Intelligent Bio plans to enter the US market with its fingerprint drug screening technology during H1 next year.
The Intelligent fingerprinting drug screening system detects the presence of specific drugs and their metabolites using fingerprint sweat analysis. Using a small, tamper-evident drug screening cartridge, the device can collect ten fingerprint sweat samples in under a minute.
The device aims to identify “current impairment”, not past use, as the test has a detection window of approximately 14–16 hours. The test is intended to be used to check for “fitness for duty” on the day and screen for common drugs of abuse such as cocaine, cannabis, methamphetamine and opiates.
The PK study aims to investigate the levels of opiates in fingerprint sweat compared with blood, oral fluid and urine samples. It will recruit 40 healthy adults and analyse the specimens using validated methods such as liquid chromatography, mass spectrometry and the Intelligent fingerprinting drug screening system.
The use of sweat testing as a method of drug detection is being developed by multiple companies. In February, the US Anti-Doping Agency partnered with Epicore to develop a sweat-sensing technology as a method of drug detection.
Epicore’s wearable sweat-collection device, Discovery Patch, comprises a wearable microfluidic patch that captures eccrine sweat directly from the skin during exercise, environmental exposure and pharmacologic modes of sweat induction. Sweat is transferred from the microfluidic patch to clean lab storage containers using a sweat extraction apparatus designed to rapidly collect and prepare sweat samples for biochemical analysis.
"Intelligent Bio begins dosing for non-invasive drug screening technology" was originally created and published by Medical Device Network, a GlobalData owned brand.
AveragePenny
9月前
$INBS Intelligent Bio Solutions to Participate in the Sidoti Small-Cap Conference on June 12-13, 2024
https://www.globenewswire.com/news-release/2024/06/06/2894659/0/en/Intelligent-Bio-Solutions-to-Participate-in-the-Sidoti-Small-Cap-Conference-on-June-12-13-2024.html
NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will participate in the Sidoti Small-Cap Conference being held virtually June 12-13, 2024.
Presentation Details
Date: Wednesday, June 12, 2024
Time: 4:00 p.m. Eastern Time
Registration/Webcast Link: https://sidoti.zoom.us/webinar/register/WN_BB5QumW3TK2N56X7MOPjpw
For more information about the conference, or to schedule a one-on-one meeting with the INBS management team, please contact your Sidoti representative or email KCSA Strategic Communications at INBS@ksca.com.
AveragePenny
11月前
Stocks to Watch for Short Squeeze Potential: DJT, INBS, IMPP, HUBC, XXII
https://thestreetreports.com/stocks-to-watch-for-short-squeeze-potential-djt-inbs-impp-hubc-xxii/
Investors must stay alert to stocks poised for a short squeeze, given the significant gains typically seen during such events. Here’s a glimpse into five stocks potentially set for a short squeeze surge in the future.
Trump Media & Technology Corp. (NASDAQ: DJT) witnessed a stellar debut last week, followed by a more subdued performance. The short interest in DJT stock, reflecting borrowed shares anticipating a price drop, hit 4.93 million, representing 12.6% of available shares. Notably, the borrowing rate spiked to 500% due to limited shortable shares, hinting at potential short covering and a share price uptick in the future.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is attracting attention this week for potential short squeeze dynamics. As a leading provider of innovative medical tech, it posted impressive financials for Q2 and the six months ending Dec 31, 2023, with a 114% revenue increase YoY for Q2 and 337% for the six months. This growth is tied to its Intelligent Fingerprinting Drug Screening System and global expansion. The stock hit an intraday high of $11.70 and closing high of $6.76 in 2024. This low-float stock is currently oversold, and the short interest in INBS stock surged to 57.64% in the latest report is adding intrigue to INBS’s stock movement.
Imperial Petroleum Inc. (NASDAQ: IMPP) is worth monitoring due to its significant short interest. On February 13, IMPP announced its financial results for the fourth quarter and fiscal year ending December 31, 2023. The company’s revenues for the quarter were $29.9 million, down from $37.9 million in the previous year, while net income decreased from $13.8 million to $6.5 million. However, for the full fiscal year, revenues rose by $86.7 million to reach $183.7 million compared to the previous year.
HUB Cyber Security Ltd. (NASDAQ: HUBC) is a potential stock to watch this week, given its focus on confidential computer cyber security solutions and services. On April 5, HUBC made headlines by securing $8 million in new financing through a straight debt arrangement. This strategic financing is aimed at bolstering the company’s financial position and enhancing its future prospects, as stated in the news release.
22nd Century Group Inc. (NASDAQ: XXII), a company focused on reducing nicotine harm in tobacco products, disclosed its financial performance for the quarter ending December 31, 2023, on March 28. The company reported a decrease in net revenues from $10 million to $7.4 million compared to the prior-year period. The operating loss widened from $10.2 million to $14.2 million year-over-year. Despite this, the gross profit surged from $0.1 million to $7.8 million in the same period.
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
glenn1919
3週前
peterus
5月前
Monksdream
6月前
